Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells

被引:45
作者
Mattu, C. [1 ]
Pabari, R. M. [2 ]
Boffito, M. [1 ]
Sartori, S. [1 ]
Ciardelli, G. [1 ,3 ]
Ramtoola, Z. [2 ]
机构
[1] Politecn Torino, Dept Mech & Aerosp Engn, I-10129 Turin, TO, Italy
[2] Royal Coll Surgeons Ireland, Sch Pharm, Dublin 2, Ireland
[3] CNR IPCF UOS Pisa, Pisa, Italy
关键词
Nanoparticles; Polyesterurethanes; Herceptin; Paclitaxel; Cancer targeting; MONOCLONAL-ANTIBODIES; DELIVERY; THERAPY; TRASTUZUMAB; EXPRESSION;
D O I
10.1016/j.ejpb.2013.07.016
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nanomedicine formulations such as biodegradable nanoparticles (nps) and liposomes offer several advantages over traditional routes of administration: due to their small size, nanocarriers are able to selectively accumulate inside tumours or inflammatory tissues, resulting in improved drug efficacy and reduced side effects. To further augment targeting ability of nanoparticles towards tumour cells, specific ligands or antibodies that selectively recognise biomarkers over-expressed on cancer cells, can be attached to the surface either by chemical bond or by hydrophilic/hydrophobic interactions. In the present work, Herceptin (HER), a monoclonal antibody (mAb) able to selectively recognise HER-2 over-expressing tumour cells (such as breast and ovarian cancer cells), was absorbed on the surface of nanoparticles through hydrophilic/hydrophobic interactions. Nps were prepared by a modified single emulsion solvent evaporation method with five different polymers: three commercial polyesters (poly(s-caprolactone) (PCL), poly (D,L-lactide) (PLA) and poly (D,L-lactide-co-.glycolide) (PLGA)) and two novel biodegradable polyesterurethanes (PURs) based on Poly(epsilon-caprolactone) blocks, synthesised with different chain extenders (1,4-cyclohexane dimethanol (CDM) and N-Boc-serinol). Polyurethanes were introduced as matrix-forming materials for nanoparticles due to their high chemical versatility, which allows tailoring of the materials final properties by properly selecting the reagents. All nps exhibited a small size and negative surface charge, suitable for surface functionalisation with mAb through hydrophilic/hydrophobic interactions. The extent of cellular internalisation was tested on two different cell lines: MCF-7 and SK-BR-3 breast cancer cells showing a normal and a high expression of the HER-2 receptor, respectively. Paclitaxel, a model anti-neoplastic drug, was encapsulated inside all nps, and release profiles and cytotoxicity on SK-BR-3 cells were also assessed. Interestingly, PUR nps were superior to commercial polyester-based nps in terms of higher cellular internalisation and cytotoxic activity on the tested cell lines. Results obtained warrants further investigation on the application of these PUR nps for controlled drug delivery and targeting. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:463 / 472
页数:10
相关论文
共 28 条
[1]   Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy [J].
Acharya, Sarbari ;
Dilnawaz, Fahima ;
Sahoo, Sanjeeb K. .
BIOMATERIALS, 2009, 30 (29) :5737-5750
[2]   Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy [J].
Arya, Geetanjali ;
Vandana, Mallaredy ;
Acharya, Sarbari ;
Sahoo, Sanjeeb K. .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2011, 7 (06) :859-870
[3]  
Birner P, 2001, CLIN CANCER RES, V7, P1669
[4]   Charged nanoparticles as protein delivery systems: A feasibility study using lysozyme as model protein [J].
Cal, Cuifang ;
Bakowsky, Udo ;
Rytting, Erik ;
Schaper, Andreas K. ;
Kissel, Thomas .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2008, 69 (01) :31-42
[5]   POLY(ESTER-ETHER-ESTER) BLOCK-COPOLYMERS AS BIOMATERIALS [J].
CERRAI, P ;
GUERRA, GD ;
LELLI, L ;
TRICOLI, M ;
DELGUERRA, RS ;
CASCONE, MG ;
GIUSTI, P .
JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE, 1994, 5 (01) :33-39
[6]   Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice [J].
Cirstoiu-Hapca, A. ;
Buchegger, F. ;
Lange, N. ;
Bossy, L. ;
Gurny, R. ;
Delie, F. .
JOURNAL OF CONTROLLED RELEASE, 2010, 144 (03) :324-331
[7]   Monoclonal antibodies and therapy of human cancers [J].
Funaro, A ;
Horenstein, AL ;
Santoro, P ;
Cinti, C ;
Gregorini, A ;
Malavasi, F .
BIOTECHNOLOGY ADVANCES, 2000, 18 (05) :385-401
[8]   Targeted drug conjugates: principles and progress [J].
Garnett, MC .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 53 (02) :171-216
[9]   Nanoparticles for drug delivery in cancer treatment [J].
Haley, Barbara ;
Frenkel, Eugene .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2008, 26 (01) :57-64
[10]   Biodegradable nanoparticles for drug delivery and targeting [J].
Hans, ML ;
Lowman, AM .
CURRENT OPINION IN SOLID STATE & MATERIALS SCIENCE, 2002, 6 (04) :319-327